c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EST
UTC-5 New York
Blue Chip
Log in
Sign up
Pasithea Therapeutics (KTTA) Reports Promising Phase 1/1b Trial Data for Neurofibromatosis Treatment
GuruFocus | Nov 13, 2026 5:50 AM EST
Related Stocks: KTTA ,
Read original article